CompletedPhase 2NCT02494570
A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa
Studying Perivascular epithelioid cell neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Aadi Bioscience, Inc.
- Principal Investigator
- Willis Navarro, MDAadi Bioscience
- Intervention
- nab-Sirolimus(drug)
- Enrollment
- 34 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2022
Study locations (9)
- Stanford University Medical Center, Palo Alto, California, United States
- Sarcoma Oncology Research Center, Santa Monica, California, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Washington University School of Medicine - Siteman Cancer Center, St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Duke University Medical Center - Duke Cancer Center, Durham, North Carolina, United States
- University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
- University of Washington - Seattle Cancer Care Alliance, Seattle, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02494570 on ClinicalTrials.gov